NDAORALTABLET
Approved
Feb 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
ALTACE (ramipril) by Pfizer is animals. Approved for hypertension, heart failure, myocardial infarction and 3 more indications. First approved in 2007.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALTACE (ramipril) is an ACE inhibitor oral tablet that reduces blood pressure and protects the heart by blocking angiotensin II formation and decreasing aldosterone secretion. It is indicated for hypertension, heart failure, post-MI management, and renal protection in diabetic patients. The drug works by inhibiting angiotensin-converting enzyme, thereby suppressing the renin-angiotensin-aldosterone system across tissue and plasma compartments.
$0.002BPart D
LOE ApproachingDeclining
Declining brand with minimal Medicare Part D spending signals reduced team investment and consolidation toward generic stewardship roles.
Mechanism of Action
animals. Angiotensin converting enzyme is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. Inhibition of ACE results in decreased plasma angiotensin II,…
Indications (6)
Worked on ALTACE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.